{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:36:27Z","timestamp":1793914587519,"version":"4.8.0"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cca.2025.120277","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:04:53Z","timestamp":1743609893000},"page":"120277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Prolactin as a novel biomarker in malignancy"],"prefix":"10.1016","volume":"572","author":[{"given":"Sami","family":"Safdari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahel","family":"Safdari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Noorabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2025.120277_b0005","unstructured":"Al-Chalabi M, Bass AN, Alsalman I. Physiology, Prolactin. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Autumn Bass declares no relevant financial relationships with ineligible companies. Disclosure: Ihsan Alsalman declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0010","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1530\/JME-13-0220","article-title":"Prolactin actions","volume":"52","author":"Horseman","year":"2014","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.cca.2025.120277_b0015","doi-asserted-by":"crossref","unstructured":"irsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review. 2022;13.","DOI":"10.3389\/fendo.2022.1002320"},{"key":"10.1016\/j.cca.2025.120277_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1001703","article-title":"The beneficial metabolic actions of prolactin","volume":"13","author":"Macotela","year":"2022","journal-title":"Front Endocrinol (lausanne)"},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0025","first-page":"56","article-title":"Prolactin Promotes Adipose Tissue Fitness and Insulin Sensitivity in Obese Males","volume":"158","author":"Ruiz-Herrera","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.cca.2025.120277_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.883092","article-title":"Severe Hyperprolactinemia Promotes Brown Adipose Tissue Whitening and Aggravates High Fat Diet Induced Metabolic Imbalance","volume":"13","author":"Lopez-Vicchi","year":"2022","journal-title":"Front Endocrinol (lausanne)."},{"key":"10.1016\/j.cca.2025.120277_b0035","doi-asserted-by":"crossref","unstructured":"Nilsson LA, Roepstorff C, Kiens B, Billig H, Ling C. Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2009;41(10):747-51.","DOI":"10.1055\/s-0029-1224181"},{"issue":"6","key":"10.1016\/j.cca.2025.120277_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101324","article-title":"Prolactin and autoimmunity: The hormone as an inflammatory cytokine","volume":"33","author":"Borba","year":"2019","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2025.120277_b0045","volume":"9","author":"Borba","year":"2018","journal-title":"Prolactin and Autoimmunity."},{"issue":"6\u20137","key":"10.1016\/j.cca.2025.120277_b0050","doi-asserted-by":"crossref","first-page":"A465","DOI":"10.1016\/j.autrev.2011.11.009","article-title":"Prolactin and autoimmunity","volume":"11","author":"Shelly","year":"2012","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11102-005-5082-5","article-title":"Prolactin and autoimmunity","volume":"8","author":"De Bellis","year":"2005","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0060","first-page":"211","article-title":"Lymphocytic hypophysitis in a patient with amenorrhea and hyperprolactinemia. A case report","volume":"31","author":"Wild","year":"1986","journal-title":"J. Reprod. Med."},{"issue":"4\u20135","key":"10.1016\/j.cca.2025.120277_b0065","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.autrev.2014.01.021","article-title":"Diagnosis and classification of autoimmune hypophysitis","volume":"13","author":"Falorni","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0070","first-page":"323","volume":"32","author":"Ramos-Martinez","year":"2021","journal-title":"The Role of Prolactin in Central Nervous System Inflammation."},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0075","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1136\/gutjnl-2013-306083","article-title":"Prolactin mediates psychological stress-induced dysfunction of regulatory T cells to facilitate intestinal inflammation","volume":"63","author":"Wu","year":"2014","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0080","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cca.2025.120277_b0085","first-page":"2)","article-title":"Prolactin and cancer: Has the orphan finally found a home? Indian Journal of","volume":"16(Suppl","author":"Sethi","year":"2012","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.cca.2025.120277_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fendo.2022.1112987","article-title":"Prolactin receptor signaling: A novel target for cancer treatment-Exploring anti-PRLR signaling strategies","volume":"13","author":"Standing","year":"2023","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.cca.2025.120277_b0095","first-page":"681","article-title":"Disorders of the anterior and posterior pituitary","volume":"39","author":"Korpi-Steiner","year":"2020"},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0100","first-page":"3","article-title":"Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues","volume":"39","author":"Saleem","year":"2018","journal-title":"The Clinical Biochemist Reviews."},{"issue":"5","key":"10.1016\/j.cca.2025.120277_b0105","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00268-012-1505-4","article-title":"Prolactin Promotes Hepatocellular Carcinoma through Janus Kinase 2","volume":"36","author":"Yeh","year":"2012","journal-title":"World JSurg."},{"key":"10.1016\/j.cca.2025.120277_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.910978","article-title":"Prolactin: The Third Hormone in Breast Cancer","volume":"13","author":"Schuler","year":"2022","journal-title":"Front Endocrinol (lausanne)."},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10552-013-0156-6","article-title":"Circulating prolactin levels and risk of epithelial ovarian cancer","volume":"24","author":"Clendenen","year":"2013","journal-title":"Cancer Causes & Control : CCC."},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0120","doi-asserted-by":"crossref","DOI":"10.35702\/onc.10013","article-title":"The Suppression of Prolactin is required for the Treatment of Advanced Prostate Cancer","volume":"2","author":"Costello","year":"2019","journal-title":"Oncogen."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1475-2867-13-103","article-title":"High expression of prolactin receptor is associated with cell survival in cervical cancer cells","volume":"13","author":"Lopez-Pulido","year":"2013","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0130","first-page":"85","article-title":"The prolactin receptor: Diverse and emerging roles in pathophysiology","volume":"2","author":"Gorvin","year":"2015","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.cca.2025.120277_b0135","doi-asserted-by":"crossref","unstructured":"Hu X, li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy. 2021;6(1):402.","DOI":"10.1038\/s41392-021-00791-1"},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2001-0036","article-title":"The role of prolactin in mammary carcinoma","volume":"24","author":"Clevenger","year":"2003","journal-title":"Endocr. Rev."},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0145","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2006.07.6356","article-title":"A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer","volume":"25","author":"Tworoger","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.cca.2025.120277_b0150","doi-asserted-by":"crossref","first-page":"10902","DOI":"10.1158\/0008-5472.CAN-06-2217","article-title":"Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9","volume":"66","author":"Cheung","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.cca.2025.120277_b0155","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.celrep.2014.03.009","article-title":"Antagonism of Tumoral Prolactin Receptor Promotes Autophagy-Related Cell Death","volume":"7","author":"Wen","year":"2014","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0160","doi-asserted-by":"crossref","first-page":"837","DOI":"10.7150\/jca.35011","article-title":"STAT3 signaling in ovarian cancer: a potential therapeutic target","volume":"11","author":"Liang","year":"2020","journal-title":"J. Cancer"},{"issue":"5","key":"10.1016\/j.cca.2025.120277_b0165","first-page":"525","article-title":"Does reserpine increase prolactin and exacerbate cancer of prostate?","volume":"2","author":"Newball","year":"1973","journal-title":"Case Control Study. Urology."},{"issue":"5","key":"10.1016\/j.cca.2025.120277_b0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1634\/theoncologist.2016-0108","article-title":"Targeting Prolactin Receptor (PRLR) Signaling in PRLR-Positive Breast and Prostate Cancer","volume":"21","author":"O'Sullivan","year":"2016","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.cca.2025.120277_b0175","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.cca.2025.120277_b0180","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1677\/ERC-08-0013","article-title":"Signal transducer and activator of transcription 5A\/B in prostate and breast cancers","volume":"15","author":"Tan","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"issue":"34","key":"10.1016\/j.cca.2025.120277_b0185","doi-asserted-by":"crossref","first-page":"15199","DOI":"10.1073\/pnas.0911651107","article-title":"Local prolactin is a target to prevent expansion of basal\/stem cells in prostate tumors","volume":"107","author":"Rouet","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.cca.2025.120277_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156253","article-title":"The effects of prolactin on the immune system, its relationship with the severity of COVID-19, and its potential immunomodulatory therapeutic effect","volume":"169","author":"Rasmi","year":"2023","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0195","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1210\/er.2004-0016","article-title":"Development and potential clinical uses of human prolactin receptor antagonists","volume":"26","author":"Goffin","year":"2005","journal-title":"Endocr. Rev."},{"issue":"10","key":"10.1016\/j.cca.2025.120277_b0200","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ncpendmet0270","article-title":"Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?","volume":"2","author":"Goffin","year":"2006","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2025.120277_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.747810","article-title":"The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers","volume":"12","author":"Ram\u00edrez-de-Arellano","year":"2021","journal-title":"Front Endocrinol (lausanne)."},{"key":"10.1016\/j.cca.2025.120277_b0210","article-title":"A Novel Mechanism of hPRL-G129R, a Prolactin Antagonist, Inhibits Human Breast Cancer Cell Proliferation and Migration","volume":"164(12):bqad158","author":"Li","year":"2023","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/1535-7163.MCT-12-0886","article-title":"Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer","volume":"12","author":"Damiano","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.cca.2025.120277_b0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ijc.2910050202","article-title":"Prolactin and mammary gland carcinogenesis. The problem of human prolactin","volume":"5","author":"Boot","year":"1970","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.cca.2025.120277_b0225","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/0002-9378(72)90879-4","article-title":"Evidence of plasma prolactin levels in patients with breast cancer","volume":"114","author":"Berle","year":"1972","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.cca.2025.120277_b0230","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/09513590.2022.2047173","article-title":"Impact of the prolactin levels in breast cancer: a systematic review and meta-analysis","volume":"38","author":"Aranha","year":"2022","journal-title":"Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology."},{"issue":"16","key":"10.1016\/j.cca.2025.120277_b0235","volume":"25","author":"Farrell","year":"2024","journal-title":"Prolactin Drives Iron Release from Macrophages and Uptake in Mammary Cancer Cells through CD44. International Journal of Molecular Sciences."},{"key":"10.1016\/j.cca.2025.120277_b0240","article-title":"Prolactin-activated PAK1 potentiates estrogen response to breast cancer cell epithelial-mesenchymal transition, migration and invasion","author":"Hammer","year":"2024","journal-title":"MicroPubl Biol."},{"issue":"6","key":"10.1016\/j.cca.2025.120277_b0245","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/endocr\/bqae039","article-title":"The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras\/MAPK Pathway","volume":"165","author":"Shen","year":"2024","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.21873\/cdp.10174","article-title":"Involvement of the PRL-PAK1 Pathway in Cancer Cell Migration","volume":"3","author":"Carrasco-Ceballos","year":"2023","journal-title":"Cancer Diagn Progn."},{"key":"10.1016\/j.cca.2025.120277_b0255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2021.01.012","article-title":"Prolactin synergizes with canonical Wnt signals to drive development of ER+ mammary tumors via activation of the Notch pathway","volume":"503","author":"O'Leary","year":"2021","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0260","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/CM9.0000000000002942","article-title":"Association between prolactin\/testosterone ratio and breast cancer in Chinese women","volume":"137","author":"Cai","year":"2024","journal-title":"Chin Med J (engl)."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0265","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13058-023-01618-3","article-title":"Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers","volume":"25","author":"Hathaway","year":"2023","journal-title":"Breast Cancer Res."},{"issue":"19","key":"10.1016\/j.cca.2025.120277_b0270","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.18632\/oncotarget.2376","article-title":"Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ER\u03b1 and STAT5","volume":"5","author":"Kavarthapu","year":"2014","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0275","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1210\/endo.138.12.5605","article-title":"Expression of prolactin and its receptor in human breast carcinoma","volume":"138","author":"Reynolds","year":"1997","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0280","first-page":"10","article-title":"Serum Prolactin Levels as a Novel, Practical Marker for Predicting Malignant Diseases of the Breast","volume":"16","author":"Singh","year":"2024","journal-title":"Cureus J Med Sci."},{"issue":"7","key":"10.1016\/j.cca.2025.120277_b0285","doi-asserted-by":"crossref","first-page":"153","DOI":"10.25303\/1907rjbt078083","article-title":"Evaluation of some hormones in female having breast cancer before and after radiotherapy","volume":"19","author":"Methaq","year":"2024","journal-title":"Res J Biotechnol."},{"issue":"11","key":"10.1016\/j.cca.2025.120277_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101195","article-title":"Prolactin enhances T regulatory cell promotion of breast cancer through the long form prolactin receptor","volume":"14","author":"Chen","year":"2021","journal-title":"Transl. Oncol."},{"issue":"11","key":"10.1016\/j.cca.2025.120277_b0295","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112662","article-title":"Suppression of breast cancer by small molecules that block the prolactin receptor","volume":"13","author":"Borcherding","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2025.120277_b0300","doi-asserted-by":"crossref","unstructured":"Chen C, Jiang J, Rao TC, Marquez Lago TT, Frank SJ, Leier A. A role for JAK2 in mediating cell surface GHR-PRLR interaction. 2023.","DOI":"10.7554\/eLife.89890.1"},{"issue":"18","key":"10.1016\/j.cca.2025.120277_b0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184685","article-title":"Crosstalk between PRLR and EGFR\/HER2 signaling pathways in breast cancer","volume":"13","author":"Kavarthapu","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0310","article-title":"The association between expression of prolactin receptor and lymph node involvement in triple-negative breast cancer. Breast Cancer","volume":"11","author":"Mohamadianamiri","year":"2023","journal-title":"Management"},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0315","doi-asserted-by":"crossref","first-page":"130","DOI":"10.21037\/gs-20-569","article-title":"Expression of long-form prolactin receptor is associated with lower disease-free and overall survival in node-negative breast cancer patients","volume":"10","author":"Sa-nguanraksa","year":"2021","journal-title":"Gland Surg."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0320","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41389-020-00297-5","article-title":"Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis","volume":"10","author":"Shams","year":"2021","journal-title":"Oncogenesis."},{"issue":"9_Supplement","key":"10.1016\/j.cca.2025.120277_b0325","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO1-24-06","article-title":"Abstract PO1-24-06: Prolactin Hormone-Induced Mammary Differentiation and Anti-tumorigenic Role in Breast Cancer","volume":"84","author":"Hamam","year":"2024","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.cca.2025.120277_b0330","article-title":"Prolactin Drives a Dynamic STAT5A\/HDAC6\/HMGN2 Cis-Regulatory Landscape Exploitable in ER+Breast Cancer","volume":"162","author":"Craig","year":"2021","journal-title":"Endocrinology (united States)"},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jpm12122086","article-title":"PRLR and CACNA2D1 Impact the Prognosis of Breast Cancer by Regulating Tumor Immunity","volume":"12","author":"Liang","year":"2022","journal-title":"J Pers Med."},{"issue":"18","key":"10.1016\/j.cca.2025.120277_b0340","doi-asserted-by":"crossref","DOI":"10.3390\/cells12182252","article-title":"Prognostic Role of Prolactin-Induced Protein (PIP) in Breast Cancer","volume":"12","author":"Sauer","year":"2023","journal-title":"Cells."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0345","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1038\/s41598-023-33707-w","article-title":"Prolactin-induced protein (PIP) increases the sensitivity of breast cancer cells to drug-induced apoptosis","volume":"13","author":"Urbaniak","year":"2023","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.cca.2025.120277_b0350","first-page":"2146","article-title":"The relationship of circulating prolactin levels to the size of primary tumor in breast cancer patients","volume":"13","author":"Pasi","year":"2023","journal-title":"National Journal of Physiology, Pharmacy and Pharmacology."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0355","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0020-7292(91)90175-5","article-title":"Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy","volume":"36","author":"Jha","year":"1991","journal-title":"Int J Gynaecol Obstet."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0360","first-page":"27","article-title":"An ovarian sex cord tumor with annular tubules secreting prolactin. Reality or fortunate coincidence?","volume":"90","author":"Kazadi Buanga","year":"1995","journal-title":"Rev Fr Gynecol Obstet."},{"key":"10.1016\/j.cca.2025.120277_b0365","doi-asserted-by":"crossref","unstructured":"Alkharusi A, AlMuslahi A, AlBalushi N, AlAjmi R, AlRawahi S, AlFarqani A, et al. Connections between prolactin and ovarian cancer. PLoS ONE. 2021;16(8 August).","DOI":"10.1371\/journal.pone.0255701"},{"issue":"9","key":"10.1016\/j.cca.2025.120277_b0370","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1055-9965.EPI-21-0139","article-title":"Prolactin and Risk of Epithelial Ovarian Cancer","volume":"30","author":"Hathaway","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.cca.2025.120277_b0375","doi-asserted-by":"crossref","DOI":"10.1530\/EDM-16-0006","article-title":"Juvenile granulosa cell tumour of the ovary presenting with hyperprolactinaemic amenorrhoea and galactorrhoea","author":"Iqbal","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"issue":"3","key":"10.1016\/j.cca.2025.120277_b0380","first-page":"15","article-title":"Human Cytomegalovirus Infection Induces High Expression of Prolactin and Prolactin Receptors in Ovarian Cancer","volume":"9","author":"Rahbar","year":"2020","journal-title":"Biology-Basel."},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0385","first-page":"183","article-title":"Diagnostic Value of Serum Prolactin in Ovarian Cancer","volume":"4","author":"Gurashi","year":"2018","journal-title":"International Biological and Biomedical Journal."},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189641","article-title":"Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers","volume":"12","author":"Gschwantler-Kaulich","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0395","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-021-08682-y","article-title":"Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial","volume":"21","author":"Hasenburg","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cca.2025.120277_b0400","doi-asserted-by":"crossref","DOI":"10.1186\/s12938-018-0581-6","article-title":"Best serum biomarker combination for ovarian cancer classification","volume":"17","author":"Song","year":"2018","journal-title":"Biomed. Eng. Online"},{"key":"10.1016\/j.cca.2025.120277_b0405","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S0090-8258(21)00861-1","article-title":"Combining the biomarkers macrophage inhibitory factor, osteopontin and prolactin with CA-125 improves early detection of ovarian cancer","volume":"162","author":"Walker","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.cca.2025.120277_b0410","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/cancers14071780","article-title":"Biomarker-Based Models for Preoperative Assessment of Adnexal Mass: A Multicenter Validation Study","volume":"14","author":"Watrowski","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.cca.2025.120277_b0415","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-16-1454","article-title":"Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity","volume":"77","author":"Sundaram","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2025.120277_b0420","series-title":"Prolactin","first-page":"233","article-title":"Actions of Prolactin in the Prostate Gland","author":"Kindblom","year":"2001"},{"key":"10.1016\/j.cca.2025.120277_b0425","doi-asserted-by":"crossref","unstructured":"Costello LC, Franklin RB. Testosterone, prolactin, and oncogenic regulation of the prostate gland. A new concept: Testosterone-independent malignancy is the development of prolactin-dependent malignancy! Oncol Rev. 2018;12(2):356.","DOI":"10.4081\/oncol.2018.356"},{"issue":"2","key":"10.1016\/j.cca.2025.120277_b0430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41419-023-06362-2","article-title":"PRL-mediated STAT5B\/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.cca.2025.120277_b0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/cancers11070929","article-title":"STAT5a\/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice","volume":"11","author":"Boutillon","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0440","first-page":"419","article-title":"Changes in prolactin receptor location in prostate tumors","volume":"74","author":"L\u00f3pez Fontana","year":"2021","journal-title":"Arch. Esp. Urol."},{"issue":"7","key":"10.1016\/j.cca.2025.120277_b0445","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad072","article-title":"Prolactin Regulates Testicular Gene Expression and Cell Cycle Processes Predominantly via JAK2\/STAT5 Pathway in the Male Rat","volume":"164","author":"Raut","year":"2023","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.cca.2025.120277_b0450","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/jme.0.0230125","article-title":"In vitro expression of long and short ovine prolactin receptors: activation of Jak2\/STAT5 pathway is not sufficient to account for prolactin signal transduction to the ovine beta-lactoglobulin gene promoter","volume":"23","author":"Bignon","year":"1999","journal-title":"J Mol Endocrinol."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0455","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1038\/s41598-017-04783-6","article-title":"Extracellular matrix promotes clathrin-dependent endocytosis of prolactin and STAT5 activation in differentiating mammary epithelial cells","volume":"7","author":"Bridgewater","year":"2017","journal-title":"Sci. Rep."},{"issue":"43","key":"10.1016\/j.cca.2025.120277_b0460","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1038\/sj.onc.1210454","article-title":"Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context","volume":"26","author":"Gutzman","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.cca.2025.120277_b0465","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41419-021-03849-8","article-title":"Oxytocin receptor induces mammary tumorigenesis through prolactin\/p-STAT5 pathway","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cca.2025.120277_b0470","doi-asserted-by":"crossref","unstructured":"Cayre S, Faraldo MM, Bardin S, Miserey-Lenkei S, Deugnier M-A, Goud BJb. RAB6 GTPase is a crucial regulator of the mammary secretory function controlling STAT5 activation. 2020.","DOI":"10.1101\/2020.03.12.989236"},{"issue":"12","key":"10.1016\/j.cca.2025.120277_b0475","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1073\/pnas.1819303116","article-title":"COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis","volume":"116","author":"Zheng","year":"2019","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0480","first-page":"391","article-title":"Low Preoperative Prolactin Levels Predict Non-Organ Confined Prostate Cancer in Clinically Localized Disease","volume":"103","author":"Porcaro","year":"2019","journal-title":"UrolInt."},{"issue":"13","key":"10.1016\/j.cca.2025.120277_b0485","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/pros.24402","article-title":"Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer","volume":"82","author":"Yang","year":"2022","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0490","doi-asserted-by":"crossref","first-page":"442","DOI":"10.26502\/jcsct.5079085","article-title":"S179D Prolactin Sensitizes Human PC3 Prostate Cancer Xenografts to Anti-tumor Effects of Well-Tolerated Doses of Calcitriol","volume":"4","author":"Holland","year":"2020","journal-title":"J Cancer Sci Clin Ther."},{"issue":"1","key":"10.1016\/j.cca.2025.120277_b0495","article-title":"A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How? J Clin Res","volume":"2","author":"Costello","year":"2019","journal-title":"Oncol."},{"issue":"9","key":"10.1016\/j.cca.2025.120277_b0500","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.21873\/anticanres.14526","article-title":"Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer","volume":"40","author":"Minami","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cca.2025.120277_b0505","article-title":"Evaluation of serum prolactin as a potential tumor marker in hepatocellular carcinoma","author":"AbdelGhani","year":"2017","journal-title":"Menoufia Medical Journal"},{"issue":"9","key":"10.1016\/j.cca.2025.120277_b0510","first-page":"948","article-title":"Relation between sex hormones and hepatocellular carcinoma","volume":"48","author":"Korah","year":"2016","journal-title":"Andrologia"},{"key":"10.1016\/j.cca.2025.120277_b0515","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canep.2018.06.009","article-title":"Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink","volume":"55","author":"Thistle","year":"2018","journal-title":"Cancer Epidemiol."},{"issue":"4","key":"10.1016\/j.cca.2025.120277_b0520","first-page":"600","article-title":"Effects of pituitary hormones and prefeeding N-hydroxy-N-2-fluorenylacetamide on the metabolism of this carcinogen and on physiologic parameters","volume":"26","author":"Shirasu","year":"1966","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.cca.2025.120277_b0525","doi-asserted-by":"crossref","first-page":"29465","DOI":"10.18632\/oncotarget.8781","article-title":"Human growth hormone and human prolactin function as autocrine\/paracrine promoters of progression of hepatocellular carcinoma","volume":"7","author":"Kong","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cca.2025.120277_b0530","first-page":"498","article-title":"Effect of DENA induced hepatocarcinogenesis on neuroendocrine levels in male rats","volume":"46","author":"Ghosh","year":"2008","journal-title":"Indian J. Exp. Biol."},{"issue":"5","key":"10.1016\/j.cca.2025.120277_b0535","first-page":"409","article-title":"Effects of prolactin and estrogen on cell proliferation of the mouse liver induced by partial hepatectomy","volume":"11","author":"Takada","year":"1997","journal-title":"In Vivo"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898125001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:30:36Z","timestamp":1754407836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898125001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":107,"alternative-id":["S0009898125001561"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2025.120277","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactin as a novel biomarker in malignancy","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2025.120277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120277"}}